Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
55 results about "Sodium Channel Inhibitors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vinpocetine is a selective inhibitor of voltage-sensitive sodium channel for the treatment of stroke, vascular dementia and Alzheimer's disease. M6006. Tetracaine. Tetracaine is a topical local anesthetic for the eyes; works by interfering with entry of sodium ions into nerve cells.
Sodium channel inhibitors
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
Owner:ICAGEN INC
Pyridone amides as modulators of sodium channels
The invention relates to pyridone amide compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels:The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
Owner:VERTEX PHARMA INC
Compositions useful as inhibitors of voltage-gated ion channels
InactiveUS20050187217A1BiocideOrganic active ingredientsSodium Channel InhibitorsVoltage-gated ion channel
Owner:VERTEX PHARMA INC
Sulfonamides as modulators of sodium channels
The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: (I). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
Owner:VERTEX PHARMA INC
Pyridone amides as modulators of sodium channels
ActiveUS9051270B2Organic chemistryNitro compound active ingredientsSodium Channel InhibitorsPharmaceutical medicine
The invention relates to pyridone amide compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels:The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
Owner:VERTEX PHARMA INC
Amides useful as inhibitors of voltage-gated sodium channels
ActiveUS20090118333A1Reduce severityBiocideNervous disorderSodium Channel InhibitorsMedicinal chemistry
Owner:VERTEX PHARMA INC
Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
InactiveCN101643458AOrganic active ingredientsNervous disorderSodium Channel InhibitorsOrganic chemistry
Owner:VERTEX PHARMA INC
Quinazolines useful as modulators of ion channels
Owner:VERTEX PHARMA INC
Methods of identifying inhibitory compounds and uses thereof
InactiveUS20020128203A1Organic active ingredientsPeptide/protein ingredientsLiddle's syndromeSodium Channel Inhibitors
The invention relates to compositions comprising a sodium channel inhibitor. Also provided are methods of identifying such inhibitors, as well as kits and pharmaceutical compositions containing the same. The invention also relates to methods of treating disorders associated with irregular or improper epithelial sodium channel ("ENAC") activity, including hypertension, renal insufficiency, electrolyte imbalances, cystic fibrosis, and Liddle's syndrome.
Owner:UNIVERSITY OF LAUSANNE
Sodium channel inhibitors
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
Owner:ICAGEN INC
Substituted quinoxalines as sodium channel modulators
The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels:The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
Owner:VERTEX PHARMA INC
Quinazolines useful as modulators of ion channels
ActiveUS20060173018A1Reduce severityBiocideOrganic active ingredientsSodium Channel InhibitorsQuinazoline
Owner:VERTEX PHARMA INC
Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
Owner:AMGEN INC
Quinazolines useful as modulators of ion channels
ActiveUS20090312342A1Reduce severityBiocideOrganic active ingredientsSodium Channel InhibitorsQuinazoline
Owner:VERTEX PHARMA INC
Topical Treatment of Peripheral diabetic complications
InactiveUS20090018151A1Decreased microcirculationEffective treatmentOrganic active ingredientsBiocideSodium Channel InhibitorsNitric oxide
This invention relates to agents for treating, ameliorating, or preventing diabetic complications specifically diabetic neuropathy and skin ulceration by topical application of materials containing one or more arterial or venous dilation components and one or more fast sodium channel inhibitors. Particularly, the invention relates to treating or ameliorating agents that contain minoxidil and its related congeners, which have both potassium channel agonist properties and nitric oxide agonist properties as an active ingredient and which are effective against diabetic complications such as neuropathy, peripheral circulation disorders and skin ulcerations. Unique methods of delivery including delivery through impregnated socks or gloves to match the distribution of pain are also noted.
Owner:FINK EZEKIEL
Pyrimidines and pyrazines useful as modulators of ion channels
Owner:VERTEX PHARMA INC
Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl
The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.
Owner:ASTELLAS PHARMA INC +1
Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels
Owner:VERTEX PHARMA INC
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
Owner:AMGEN INC
Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl
The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.
Owner:ASTELLAS PHARMA INC +1
Sodium channel inhibitors
Owner:ICAGEN INC
Quinazolines useful as modulators of voltage gated ion channels
InactiveUS20080221137A1BiocideOrganic active ingredientsSodium Channel InhibitorsVoltage-gated ion channel
Owner:VERTEX PHARMA INC
Pharmaceutical Compositions for Combination Therapy
InactiveUS20150164871A1Improve adverse reactionsGood treatment effectBiocideAnimal repellantsSodium Channel InhibitorsPotassium
Owner:ACESION PHARMA APS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com